Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. She’s deep into researching targeted therapies for lung cancer so she can offer up better treatment options.
The disease has been the leading cause of cancer deaths for a long time, but researchers like her are making some progress. Along these lines, Reckamp recently presented a study at lung cancer conference in Chicago on a possible test to help choose the most effective therapy for patients with the most common form of lung cancer. The test might predict which non-small-cell lung cancer patients would respond better to a combination treatment, rather than one drug alone.
It all comes down to a blood test called VeriStrat. (Read more at City of Hope’s Breakthroughs)